Skip to content

Valion Bio, Inc.

Public company
Headquarters
SAN ANTONIO, Texas
Ticker
VBIO
CIK
0001787740

WARN notices since 2024

0
None on record

Workers affected since 2024

0
Across 0 notices

Executive changes, last 12 months

10
6 appointments, 4 departures

Last event

Nov 5, 2026
Executive departurePresident departs: Lisa Wolf

Workers affected over time

Cumulative workers in WARN notices since 2024

Not enough notices to chart yet.

Leadership

Role and personSinceChange
PresidentLisa WolfNov 5, 2026Departed
CLOMelinda LackeyNov 2, 2026Departed
CEODean ZikriaSep 23, 2026Appointed
directorSheryle BoltonSep 23, 2026Departed
chairThomas JensenSep 23, 2026Appointed
member of the board of directorsJared MalbinSep 1, 2026Appointed
member of the BoardThomas JensenSep 1, 2026Appointed
COOLisa WolfAug 17, 2026Appointed
CEOMichael K. HandleyAug 17, 2026Departed

Related companies

Same industry and state, with recent events.

  1. Executive departure

    President departs: Lisa Wolf

    Lisa Wolf, President of Valion Bio, Inc., resigns the role, effective December 11, 2026. The company reported the change in an 8-K that cites Item 5.02.

    Role: President

    Source: SEC 8-K, filed Nov 5, 2026

  2. Executive departure

    CLO departs: Melinda Lackey

    Melinda Lackey, General Counsel and Senior Vice President of Legal Affairs of Valion Bio, Inc., leaves the role, effective October 30, 2026. The company reported the change in an 8-K that cites Item 5.02.

    Role: General Counsel and Senior Vice President of Legal Affairs

    Source: SEC 8-K, filed Nov 2, 2026

  3. Executive appointment

    CEO appointed: Dean Zikria

    Dean Zikria was named ceo of Valion Bio, Inc., effective September 22, 2026. The company reported the change in an 8-K that cites Item 5.02.

    Role: ceo

    Source: SEC 8-K, filed Sep 23, 2026

  4. Executive departure

    director departs: Sheryle Bolton

    Sheryle Bolton, director of Valion Bio, Inc., resigns the role, effective September 17, 2026. The company reported the change in an 8-K that cites Item 5.02.

    Role: director

    Source: SEC 8-K, filed Sep 23, 2026

  5. Executive appointment

    chair appointed: Thomas Jensen

    Thomas Jensen was named chair of Valion Bio, Inc., effective September 17, 2026. The company reported the change in an 8-K that cites Item 5.02.

    Role: chair

    Source: SEC 8-K, filed Sep 23, 2026

  6. Executive appointment

    chair appointed: Jared Malbin

    Jared Malbin was named chair of Valion Bio, Inc., effective September 17, 2026. The company reported the change in an 8-K that cites Item 5.02.

    Role: chair

    Source: SEC 8-K, filed Sep 23, 2026

  7. Executive appointment

    member of the board of directors appointed: Jared Malbin

    Jared Malbin was named member of the board of directors of Valion Bio, Inc., effective August 27, 2026. The company reported the change in an 8-K that cites Item 5.02.

    Role: member of the board of directors

    Source: SEC 8-K, filed Sep 1, 2026

  8. Executive appointment

    member of the Board appointed: Thomas Jensen

    Thomas Jensen was named member of the Board of Valion Bio, Inc., effective August 27, 2026. The company reported the change in an 8-K that cites Item 5.02.

    Role: member of the Board

    Source: SEC 8-K, filed Sep 1, 2026

Last verified Nov 8, 2026